Journal articleAnticancer Drugs2022
Mechanisms of GZ17-6.02 resistance.
- Journal
- Anticancer Drugs
- Published
- 1 June 2022
- Citations
- 5
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Objectives The drug GZ17-6.02 is undergoing phase I in solid tumor patients (NCT03775525). The present studies initially determined the impact of prolonged exposure of colorectal tumors to GZ17-6.02, and to determine whether GZ17-6.02 enhanced the efficacy of an anti-PD1 antibody. … Excerpt only: this text is the publisher’s. Read it in full at the source.